

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2015

**CYCLACEL PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-50626  
(Commission File Number)

91-1707622  
(IRS Employer  
Identification No.)

200 Connell Drive, Suite 1500  
Berkeley Heights, NJ 07922  
(Address of principal executive offices and zip code)  
Registrant's telephone number, including area code: (908) 517-7330

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## Item 2.02 Results of Operations and Financial Condition.

The information set forth under this “Item 2.02. Results of Operations and Financial Condition,” including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Attached as Exhibit 99.1 is a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the “Company”), dated November 12, 2015, announcing certain financial results for the third quarter ended September 30, 2015.

The Company will conduct a conference call to review its financial results on November 12, 2015, at 4:30 p.m., Eastern Time.

## Forward-Looking Statements

This Form 8-K contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at [www.sec.gov](http://www.sec.gov). Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

## Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| <b>Exhibit<br/>Number</b> | <b>Description</b>  |
|---------------------------|---|
| 99.1                      | Press release announcing financial results for the third quarter ended September 30, 2015, dated November 12, 2015. |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CYCLACEL PHARMACEUTICALS, INC.**

By: /s/ Paul McBarron  
Name: Paul McBarron  
Title: Executive Vice President—Finance,  
Chief Financial Officer and Chief Operating Officer

Date: November 12, 2015

---



Cyclacel Pharmaceuticals, Inc.

## P R E S S R E L E A S E

**Cyclacel Pharmaceuticals Reports Third Quarter 2015 Financial Results**

*Conference Call Scheduled November 12, 2015 at 4:30 p.m. EST*

BERKELEY HEIGHTS, N.J., Nov. 12, 2015 - Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2015.

The Company's net loss applicable to common shareholders for the third quarter ended September 30, 2015 was \$2.8 million, or \$0.08 per basic and diluted share, compared to a net loss applicable to common shareholders of \$5.0 million, or \$0.22 per basic and diluted share for the third quarter ended September 30, 2014. As of September 30, 2015, cash and cash equivalents totaled \$22.7 million.

"SEAMLESS continues to progress towards final data read-out," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. "There are now approximately 8% of events remaining to occur and we anticipate reporting top-line data during the first half of 2016. Following unblinding and analysis of the data, we will review the results to determine their suitability for submission to regulators. Our CDK2/9 programs made significant progress over the quarter. The CYC065 Phase 1 trial in solid tumor and lymphoma patients has started and the mechanistic rationale for CDK2/9 inhibition in targeted solid tumors and hematological malignancies is supported by multiple presentations at scientific conferences. Seliciclib was administered to the first patients with Cushing's disease in an investigator-sponsored trial. We and our investigators are excited about the prospects of CDK2/9 inhibitors and we look forward to keeping you apprised as to our progress."

**Business Highlights**
***Sapacitabine in SEAMLESS, pivotal, Phase 3 study for first-line treatment in elderly patients with acute myeloid leukemia (AML):***

- Continued follow-up with 8% of events remaining before analyzing mature data and reporting top-line results. The SEAMLESS study is powered at 90% to detect a 27.5% improvement of survival between the experimental and control arms.

***Cyclin Dependent Kinase (CDK) Inhibitor Programs***

- Presented the molecular rationale for clinical development of CYC065 for the treatment of solid tumors at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
- Dosed the first patient in a first-in-human, Phase 1 trial of CYC065, the Company's second-generation CDK2/9 inhibitor, in solid tumor and lymphoma patients to evaluate the safety, tolerability and pharmacokinetic profile of CYC065

200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 USA T: +1 (908) 517 7330 F: +1 (866) 271 3466

Dundee Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067

[www.cyclacel.com](http://www.cyclacel.com) – [info@cyclacel.com](mailto:info@cyclacel.com)

- Presented the molecular rationale for clinical development of CYC065 for the treatment of leukemias and lymphomas at the Society of Hematologic Oncology (SOHO) 2015 Annual Meeting
- Dosed the first patient in a Phase 2 investigator-sponsored trial (IST) evaluating seliciclib as a potential treatment for Cushing's disease.
- CYC065 data to be presented at the upcoming 2015 San Antonio Breast Cancer Symposium in Texas and at the 4<sup>th</sup> Neuroblastoma Symposium in Newcastle Upon Tyne, United Kingdom

### **Third Quarter 2015 Financial Results**

#### ***Revenue***

Revenue was \$0.7 million for both the three months ended September 30, 2014 and 2015. Revenue is mainly related to grants from the European Union and the Biomedical Catalyst of the United Kingdom government. The Company recognized \$0.3 million from its license and supply agreement with ManRos during the three months ended September 30, 2015.

#### ***Research and Development Expenses***

Research and development expenses were \$2.9 million for the three months ended September 30, 2015, compared to \$5.0 million for the same period in the previous year. The decrease was primarily a result of reduced expenditures in study and site startup costs associated with the SEAMLESS Phase 3 study this quarter compared to the same period last year.

#### ***General and Administrative Expenses***

General and administrative expenses for the three months ended September 30, 2015 were \$1.2 million compared to \$1.4 million for the same period in 2014. The decrease was primarily the result of lower patent-related and stock-based compensation costs.

#### **Conference call and Webcast Information:**

Cyclacel will conduct a conference call on November 12, 2015 at 4:30 p.m. Eastern Time to review the third quarter 2015 results. Conference call and webcast details are as follows:

Conference call information:

US/Canada call: (877) 493-9121/ international call: (973) 582-2750

US/Canada archive: (800) 585-8367 / international archive: (404) 537-3406

Code for live and archived conference call is 63652219

For the live and archived webcast, please visit the Corporate Presentations and Events page on the Cyclacel website at [www.cyclacel.com](http://www.cyclacel.com). The webcast will be archived for 90 days and the audio replay for 7 days.

#### **About Cyclacel Pharmaceuticals, Inc.**

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for

myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer and in particular those patients carrying BRCA mutations. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. Please visit [www.cyclacel.com](http://www.cyclacel.com) for additional information.

### **Forward-looking Statements**

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at [www.sec.gov](http://www.sec.gov). Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

**CYCLACEL PHARMACEUTICALS, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**

(In \$000s, except share and per share amounts)  
(Unaudited)

|   | Three Months Ended<br>September 30, |                   | Nine months Ended<br>September 30, |                    |
|---|-------------------------------------|-------------------|------------------------------------|--------------------|
|   | 2014                                | 2015              | 2014                               | 2015               |
| <b>Revenues:</b>  |                                     |                   |                                    |                    |
| Grant revenue   | \$ 735                              | \$ 462            | \$ 1,487                           | \$ 1,270           |
| Collaboration and research and development revenue                                    | —                                   | 253               | —                                  | 253                |
| <b>Total revenues</b>   | <b>735</b>                          | <b>715</b>        | <b>1,487</b>                       | <b>1,523</b>       |
| <b>Operating expenses:</b>  |                                     |                   |                                    |                    |
| Research and development  | 4,972                               | 2,904             | 13,861                             | 9,826              |
| General and administrative  | 1,433                               | 1,205             | 4,281                              | 4,006              |
| <b>Total operating expenses</b>   | <b>6,405</b>                        | <b>4,109</b>      | <b>18,142</b>                      | <b>13,832</b>      |
| <b>Operating loss</b>   | <b>(5,670)</b>                      | <b>(3,394)</b>    | <b>(16,655)</b>                    | <b>(12,309)</b>    |
| Other income (expense):   |                                     |                   |                                    |                    |
| Change in valuation of financial instruments associated with stock purchase agreement | (4)                                 | (27)              | (115)                              | (51)               |
| Change in valuation of liabilities measured at fair value                             | —                                   | —                 | 20                                 | —                  |
| Foreign exchange gains (losses)   | 10                                  | 219               | (23)                               | (354)              |
| Interest income   | 3                                   | 2                 | 5                                  | 5                  |
| Other income, net   | —                                   | 13                | 26                                 | 95                 |
| Total other income (expense)  | 9                                   | 207               | (87)                               | (305)              |
| <b>Loss from continuing operations before taxes</b>                                   | <b>(5,661)</b>                      | <b>(3,187)</b>    | <b>(16,742)</b>                    | <b>(12,614)</b>    |
| Income tax benefit  | 750                                 | 478               | 2,135                              | 1,646              |
| <b>Net loss from continuing operations</b>  | <b>(4,911)</b>                      | <b>(2,709)</b>    | <b>(14,607)</b>                    | <b>(10,968)</b>    |
| <b>Discontinued operations:</b>   |                                     |                   |                                    |                    |
| Income from discontinued operations   | 6                                   | —                 | 29                                 | —                  |
| Income tax on discontinued operations   | (2)                                 | —                 | (10)                               | —                  |
| <b>Net income from discontinued operations</b>  | <b>4</b>                            | <b>—</b>          | <b>19</b>                          | <b>—</b>           |
| <b>Net loss</b>   | <b>(4,907)</b>                      | <b>(2,709)</b>    | <b>(14,588)</b>                    | <b>(10,968)</b>    |
| Dividend on convertible exchangeable preferred shares                                 | (50)                                | (50)              | (150)                              | (150)              |
| <b>Net loss applicable to common shareholders</b>                                     | <b>\$ (4,957)</b>                   | <b>\$ (2,759)</b> | <b>\$ (14,738)</b>                 | <b>\$ (11,118)</b> |
| <b>Basic and diluted earnings per common share:</b>                                   |                                     |                   |                                    |                    |
| Net loss per share, continuing operations – basic and diluted                         | \$ (0.22)                           | \$ (0.08)         | \$ (0.68)                          | \$ (0.35)          |
| Net income per share, discontinued operations – basic and diluted                     | \$ 0.00                             | \$ 0.00           | \$ 0.00                            | \$ 0.00            |
| Net loss per share – basic and diluted  | \$ (0.22)                           | \$ (0.08)         | \$ (0.68)                          | \$ (0.35)          |
| Weighted average common shares outstanding  | 22,676,475                          | 34,675,569        | 21,607,888                         | 31,741,910         |

**CYCLACEL PHARMACEUTICALS, INC.  
CONSOLIDATED BALANCE SHEETS**

(In \$000s, except share, per share, and liquidation preference amounts)

|  | December 31,<br>2014 | September 30,<br>2015<br>(Unaudited) |
|--|----------------------|--------------------------------------|
| <b>ASSETS</b>  |                      |                                      |
| Current assets:  |                      |                                      |
| Cash and cash equivalents  | \$ 24,189            | \$ 22,728                            |
| Prepaid expenses and other current assets  | 4,640                | 3,966                                |
| Current assets of discontinued operations  | 171                  | 100                                  |
| Total current assets   | 29,000               | 26,794                               |
| Property, plant and equipment (net)  | 387                  | 255                                  |
| Total assets   | \$ 29,387            | \$ 27,049                            |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>  |                      |                                      |
| Current liabilities:   |                      |                                      |
| Accounts payable   | \$ 2,792             | \$ 1,616                             |
| Accrued and other current liabilities  | 4,626                | 3,572                                |
| Current liabilities of discontinued operations   | 75                   | 75                                   |
| Total current liabilities  | 7,493                | 5,263                                |
| Other liabilities  | 206                  | 186                                  |
| Total liabilities  | 7,699                | 5,449                                |
| Commitments and contingencies  |                      |                                      |
| Stockholders' equity:  |                      |                                      |
| Preferred stock, \$0.001 par value; 5,000,000 shares authorized at December 31, 2014 and September 30, 2015; 335,273 shares issued and outstanding at December 31, 2014 and September 30, 2015.<br>Aggregate preference in liquidation of \$3,989,749 at December 31, 2014 and September 30, 2015. | —                    | —                                    |
| Common stock, \$0.001 par value; 100,000,000 shares authorized at December 31, 2014 and September 30, 2015; 23,199,469 and 34,702,910 shares issued and outstanding at December 31, 2014 and September 30, 2015, respectively.   | 23                   | 34                                   |
| Additional paid-in capital   | 330,962              | 341,891                              |
| Accumulated other comprehensive loss   | (480)                | (540)                                |
| Accumulated deficit  | (308,817)            | (319,785)                            |
| Total stockholders' equity   | 21,688               | 21,600                               |
| Total liabilities and stockholders' equity   | \$ 29,387            | \$ 27,049                            |

**Source: Cyclacel Pharmaceuticals, Inc.**

Contacts for Cyclacel Pharmaceuticals, Inc.

Company: Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com

Investor Relations: Russo Partners LLC, Robert Flamm, (212) 845-4226, robert.flamm@russopartnersllc.com